{"filings":[{"id":2243876,"accession_number":"0001193125-26-349133","cik":2035832,"company_name":"Aktis Oncology, Inc.","ticker":"AKTS","form_type":"8-K","filed_at":"2026-08-13T20:04:16+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aktis Oncology Q2 net loss $24.1M; cash $517.3M funds operations into 2029","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $24.1M for Q2 2026 vs $18.1M prior-year; interest income net of $4.8M.","Cash, equivalents, marketable securities $517.3M at June 30, 2026 vs $226.8M Dec 31, 2025.","Collaboration revenue $3.4M (Q2 2026) vs $1.6M prior-year, from Eli Lilly partnership.","R&D expenses $25.3M, up from $18.6M; G&A $7.0M vs $3.9M year-over-year.","Phase 1b trials: AKY-1189 (NECTINIUM-2) enrolling; AKY-2519 BActinium-2 to start H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1124343251.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":12801,"accession_number":"0001193125-26-216716","cik":2035832,"company_name":"Aktis Oncology, Inc.","ticker":"AKTS","form_type":"8-K","filed_at":"2026-05-11T20:04:15+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aktis Oncology Q1 2026 net loss $18.3M; cash $538.5M; Phase 1b trials advancing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $18.3M vs $15.0M YoY; R&D expense $20.0M (+$4.1M) driven by clinical trial costs.","Cash, equivalents & marketable securities $538.5M (up from $226.8M Dec 2025); runway into 2029.","Initiated Phase 1b trial of AKY-2519 in mCRPC; second basket trial in H2 2026 for solid tumors.","AKY-1189 Phase 1b enrolling in multiple Nectin-4 tumors; preliminary data expected Q1 2027; FDA Fast Track for urothelial cancer.","Collaboration revenue $3.2M from Eli Lilly; appointed Glenn Gormley, MD, PhD to board."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":3227000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1124343251.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97406,"accession_number":"0001193125-26-158944","cik":2035832,"company_name":"Aktis Oncology, Inc.","ticker":"AKTS","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Aktis Oncology appoints Glenn Gormley to board; two directors resign","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Glenn Gormley, MD, PhD appointed independent director and co-chair of new Science and Technology Committee, effective April 15, 2026.","Gormley, 72, previously Global Head of R&D at Daiichi Sankyo; over 30 years biopharma leadership.","Received option for 37,866 shares vesting over three years; annual cash compensation $45,000 plus $15,000 for committee role.","Helen S. Kim and Oleg Nodelman resign from board effective May 20, 2026; not due to any disagreement.","Gormley joins as company advances clinical milestones in targeted radiopharmaceuticals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1124343251.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112140,"accession_number":"0001193125-26-132524","cik":2035832,"company_name":"Aktis Oncology, Inc.","ticker":"AKTS","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aktis Oncology: FDA clears IND for AKY-2519; full-year 2025 net loss widens to $63.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA cleared IND for AKY-2519 (B7-H3 miniprotein radioconjugate); Phase 1b trial for solid tumors expected mid-2026.","AKY-1189 (Nectin-4) granted Fast Track designation for urothelial cancer in Feb 2026; Phase 1b enrolling.","Pro forma cash of $562.1M (incl. $335.3M net from Jan 2026 IPO) expected to fund operations into 2029.","FY2025 net loss $63.7M vs $44.0M; R&D spend $67.5M (+65% YoY) driven by clinical advancement.","Collaboration revenue from Eli Lilly partnership totaled $6.5M in FY2025, up from $1.5M in FY2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1124343251.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112139,"accession_number":"0001193125-26-010354","cik":2035832,"company_name":"Aktis Oncology, Inc.","ticker":"AKTS","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Aktis Oncology adopts classified board, supermajority vote, and eliminates written consent post-IPO","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Filed amended charter authorizing 480M shares of common, 10M Class A common, and 10M undesignated preferred stock.","Adopted classified board with staggered three-year terms; removal of directors requires two-thirds vote for cause.","Eliminated stockholder action by written consent in lieu of meetings.","Amended bylaws to establish procedures for stockholder proposals and director nominations.","All changes effective Jan 12, 2026 in connection with IPO completion, as previously disclosed in S-1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1124343251.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}